New CLL strategy spares patients unnecessary drugs
NCT ID NCT05650723
First seen Mar 07, 2026 · Last updated May 23, 2026 · Updated 12 times
Summary
This study tests a new way to treat chronic lymphocytic leukemia (CLL) using two oral drugs, zanubrutinib and venetoclax. Instead of giving everyone a third drug from the start, only patients who still have signs of cancer after initial treatment will receive the additional drug obinutuzumab. The goal is to reduce side effects and improve results by tailoring therapy to each person's response. About 50 adults with CLL will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Weill Cornell Medicine/NewYork-Presberteryian Hospital
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.